Pravachol Exclusivity Case Remanded To FDA By Appeals Court
This article was originally published in The Tan Sheet
Executive Summary
FDA needs to develop policy clarifying how the voluntary dismissal of a patent litigation proceeding impacts a generic drug maker's 180-day exclusivity period, according to a D.C. federal appeals court decision issued March 16